Clinical Trials Resource Center

Panic Disorders

June 16, 2008

Alexza reported negative results from a phase IIa trial of AZ-002 (Staccato alprazolam) for the treatment of panic disorder. This randomized, double-blind, placebo-controlled study enrolled 40 subjects in the US. Following an open label phase, the subjects received a Staccato device (randomized to either 1 mg AZ-002 or placebo) and an intravenous administration of doxapram, a respiratory stimulant used to induce a simulated panic attack. The co-primary endpoints were to assess the effect of treatment on the occurrence of a doxapram-induced panic attack of sufficient intensity and to assess the effect of treatment on the duration of the doxapram-induced panic attack. Data was based on the Acute Panic Inventory, a 22-item self-report questionnaire. The trial failed to reach statistical significance on both primary endpoints. AZ-002 was safe and well tolerated and no serious adverse events were reported. Alexza plans to further analyze the data in order to determine a future course of action.

This information does not represent a Lupus Research Institute endorsement of any listed study. It is merely a notice that the study is available. If you are presently under the care of a physician for lupus or other conditions, you should not disrupt your current program without discussing it with your doctor(s). Do not contact the Lupus Research Institute for information on these studies. Only contact the listed numbers. The Lupus Research Institute does not have any jurisdiction over or further involvement with these studies, other than to make people aware that they are being conducted.